There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NovoCure (NVCR) and Inotiv (NOTV) with bullish sentiments.
NovoCure (NVCR)
In a report released today, Jason Wittes from Northland Securities maintained a Buy rating on NovoCure, with a price target of $250.00. The company’s shares closed last Tuesday at $197.33, close to its 52-week high of $218.09.
According to TipRanks.com, Wittes is a 5-star analyst with an average return of 16.9% and a 63.0% success rate. Wittes covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Alphatec Holdings, and Globus Medical.
NovoCure has an analyst consensus of Moderate Buy, with a price target consensus of $194.50, representing a -1.8% downside. In a report released today, Mizuho Securities also reiterated a Buy rating on the stock with a $242.00 price target.
See today’s analyst top recommended stocks >>
Inotiv (NOTV)
In a report released today, Kyle Bauser from Colliers Securities reiterated a Buy rating on Inotiv, with a price target of $25.00. The company’s shares closed last Tuesday at $20.95, close to its 52-week high of $21.40.
According to TipRanks.com, Bauser is a 4-star analyst with an average return of 11.7% and a 58.3% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Chembio Diagnostics.
Inotiv has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
